Relative search popularity of five advanced prostate cancer medications using Google Trends-Reference-Cited by-同舟云学术

Relative search popularity of five advanced prostate cancer medications using Google Trends

Published:2023-09-08 Issue: Volume: Page:
ISSN:1365-7852
Container-title:Prostate Cancer and Prostatic Diseases
language:en
Short-container-title:Prostate Cancer Prostatic Dis

Author:

Das Sanjay^ORCID,Friedrich Nadine A.^ORCID,Daniels James^ORCID,Galvan G. Cecilia^ORCID,Gong Jun^ORCID,Posadas Edwin^ORCID,Aronson William^ORCID,Freedland Stephen J.^ORCID

Funder

U.S. Department of Health & Human Services | National Institutes of Health

U.S. Department of Defense

Prostate Cancer Foundation

American Cancer Society

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Urology,Oncology

Link

https://www.nature.com/articles/s41391-023-00716-9.pdf

Reference24 articles.

1. Desai K, McManus JM, Sharifi N. Hormonal therapy for prostate cancer. Endocr Rev. 2021;42:354–73. https://doi.org/10.1210/endrev/bnab002.

2. Mori K, Mostafaei H, Pradere B, Motlagh RS, Quhal F, Laukhtina E, et al. Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis. Int J Clin Oncol. 2020;25:1892–900. https://doi.org/10.1007/s10147-020-01777-9.

3. Vaishampayan UN, Heilbrun LK, Monk P 3rd, Tejwani S, Sonpavde G, Hwang C, et al. Clinical efficacy of enzalutamide vs bicalutamide combined with androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: a randomized clinical trial. JAMA Netw Open. 2021;4:e2034633. https://doi.org/10.1001/jamanetworkopen.2020.34633.

4. Koukourakis MI, Kakouratos C, Kalamida D, Mitrakas A, Pouliliou S, Xanthopoulou E, et al. Comparison of the effect of the antiandrogen apalutamide (ARN-509) versus bicalutamide on the androgen receptor pathway in prostate cancer cell lines. Anticancer Drugs. 2018;29:323–33. https://doi.org/10.1097/cad.0000000000000592.

5. Ueda T, Shiraishi T, Ito S, Ohashi M, Matsugasumi T, Yamada Y, et al. Abiraterone acetate versus bicalutamide in combination with gonadotropin releasing hormone antagonist therapy for high risk metastatic hormone sensitive prostate cancer. Sci Rep. 2021;11:10094. https://doi.org/10.1038/s41598-021-89609-2.